BR112017006918A2 - formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares - Google Patents

formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares

Info

Publication number
BR112017006918A2
BR112017006918A2 BR112017006918A BR112017006918A BR112017006918A2 BR 112017006918 A2 BR112017006918 A2 BR 112017006918A2 BR 112017006918 A BR112017006918 A BR 112017006918A BR 112017006918 A BR112017006918 A BR 112017006918A BR 112017006918 A2 BR112017006918 A2 BR 112017006918A2
Authority
BR
Brazil
Prior art keywords
treatment
active ingredients
eye diseases
silibin
release
Prior art date
Application number
BR112017006918A
Other languages
English (en)
Inventor
Rita Blanco Anna
LA MARCA Clara
ESPOSITO Emanuela
Fabiola Craparo Emanuela
Giammona Gaetano
CAVALLARO Gennara
Pitarresi Giovanna
Granata Giuseppe
Maria Letizia Consoli Grazia
Deidda Irene
Luisa Bondi' Maria
LICCIARDI Mariano
GUARNERI Patrizia
SALADINO Patrizia
Cuzzocrea Salvatore
PAPASERGI Salvatore
VIOLA Santa
Original Assignee
Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L filed Critical Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L
Publication of BR112017006918A2 publication Critical patent/BR112017006918A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/92—Systems containing at least three condensed rings with a condensed ring system consisting of at least two mutually uncondensed aromatic ring systems, linked by an annular structure formed by carbon chains on non-adjacent positions of the aromatic system, e.g. cyclophanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

são descritas formulações que contêm silibinina ou outros ingredientes ativos incorporados em sistemas de nanopartículas lipídicas do tipo sln e nlc e à base de calixarenos, possivelmente mucoadesivos, ou em sistemas micelares e de nanopartículas à base de copolímeros anfifílicos de inulina, para utilização no tratamento de doenças oculares neurodegenerativas. a versatilidade do composto de calixareno é também descrita, capaz de carregar e liberar ingredientes ativos, caracterizados por baixa solubilidade em água, fácil degradação química e enzimática, baixa biodisponibilidade, de origem natural ou não, a ser utilizado no tratamento de doenças oculares.
BR112017006918A 2014-10-09 2015-10-09 formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares BR112017006918A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI20140230 2014-10-09
PCT/IB2015/057732 WO2016055976A1 (en) 2014-10-09 2015-10-09 Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases

Publications (1)

Publication Number Publication Date
BR112017006918A2 true BR112017006918A2 (pt) 2017-12-12

Family

ID=52444403

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006918A BR112017006918A2 (pt) 2014-10-09 2015-10-09 formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares

Country Status (13)

Country Link
US (3) US11266659B2 (pt)
EP (2) EP3587392B1 (pt)
JP (1) JP6744862B2 (pt)
CN (3) CN112022808A (pt)
AU (2) AU2015329609B2 (pt)
BR (1) BR112017006918A2 (pt)
CA (1) CA2963872C (pt)
ES (2) ES2905458T3 (pt)
IL (2) IL251555B (pt)
MX (2) MX2020001812A (pt)
PL (1) PL3203989T3 (pt)
RU (2) RU2019134423A (pt)
WO (1) WO2016055976A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015329609B2 (en) * 2014-10-09 2021-01-21 Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
US11918659B2 (en) 2018-09-20 2024-03-05 University Of Miami Materials and methods for inducing therapeutic hypothermia in a mammalian subject
CN112022848B (zh) * 2020-08-13 2022-02-22 中南大学湘雅二医院 索拉非尼在治疗1型糖尿病中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2306684T3 (es) 2001-09-17 2008-11-16 Nanopart-C S.A. Nuevo sistema coloidal dispersable a base de calixareno en forma de nanoparticulas.
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
JP5209302B2 (ja) 2004-06-15 2013-06-12 ポリメディックス、インク． ポリカチオン化合物とその使用
FR2899900A1 (fr) 2006-04-18 2007-10-19 Centre Nat Rech Scient Derives de calixarenes comme agent anticancereux
US20070298069A1 (en) * 2006-06-26 2007-12-27 Boston Scientific Scimed, Inc. Medical devices for release of low solubility therapeutic agents
US8252954B2 (en) 2007-06-07 2012-08-28 The Curators Of The University Of Missouri Processes for the preparation of calixarene derivatives
PT2219642E (pt) 2007-11-15 2011-10-18 Madaus Gmbh Componente de silibinina para o tratamento de hepatite
CN101627970A (zh) 2008-07-17 2010-01-20 北京北大维信生物科技有限公司 一种药物固体脂质纳米颗粒的制备方法
EP2156834A1 (en) 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101554371A (zh) 2009-04-13 2009-10-14 中国药科大学 水飞蓟宾和水飞蓟素聚合物胶束的制备和应用
CN101632638B (zh) * 2009-08-21 2011-04-20 山东大学 一种水飞蓟宾纳米脂质载体及其制备方法
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
CN102949344A (zh) 2011-08-30 2013-03-06 同济大学 一种姜黄素固体脂质纳米粒作为治疗哮喘药物的应用
EP2804592B1 (en) 2012-01-20 2019-08-14 South Dakota State University Inulin and inulin acetate formulations
US9707186B2 (en) * 2012-02-21 2017-07-18 Amrita Vishwa Vidyapeetham Core-shell particle formulation for delivering multiple therapeutic agents
CN104661647A (zh) * 2012-05-03 2015-05-27 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
EP2664329A1 (de) 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US20150272992A1 (en) * 2012-10-24 2015-10-01 The Texas A&M University System Treatment of Tumors with Activated Mesenchymal Stem Cells
AU2013384818A1 (en) * 2013-03-27 2015-11-12 Comprehensive Drug Enterprises, Ltd. Ophthalmic composition, method for preparing the same, and use of the same
CN103655519A (zh) * 2013-12-24 2014-03-26 哈尔滨医科大学 一种具有P-gp抑制作用的姜黄素固体脂质纳米粒及制备方法
CN103655214A (zh) 2013-12-27 2014-03-26 苏州纳康生物科技有限公司 负载四氢姜黄素的纳米载体及其制备方法
CN103784421B (zh) 2014-02-27 2016-04-27 哈尔滨医科大学 载姜黄素和胡椒碱的固体脂质纳米粒及其制备方法
AU2015329609B2 (en) * 2014-10-09 2021-01-21 Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases

Also Published As

Publication number Publication date
CA2963872C (en) 2023-09-12
IL270159B (en) 2021-03-25
US20220031614A1 (en) 2022-02-03
RU2017115575A (ru) 2018-11-13
ES2905458T3 (es) 2022-04-08
MX2020001812A (es) 2021-11-30
RU2019134423A (ru) 2019-11-19
EP3587392A8 (en) 2020-05-27
ES2756752T3 (es) 2020-04-27
CA2963872A1 (en) 2016-04-14
US20170216309A1 (en) 2017-08-03
JP6744862B2 (ja) 2020-08-19
EP3587392B1 (en) 2021-11-03
IL251555A0 (en) 2017-05-29
CN112022808A (zh) 2020-12-04
WO2016055976A1 (en) 2016-04-14
JP2017530989A (ja) 2017-10-19
MX2017004649A (es) 2017-11-30
AU2021202374A1 (en) 2021-05-13
IL251555B (en) 2020-07-30
US11266659B2 (en) 2022-03-08
CN112022807A (zh) 2020-12-04
EP3203989B1 (en) 2019-08-21
EP3587392A1 (en) 2020-01-01
RU2017115575A3 (pt) 2019-07-17
PL3203989T3 (pl) 2020-06-29
US20210046083A1 (en) 2021-02-18
AU2021202374B2 (en) 2022-12-01
EP3203989A1 (en) 2017-08-16
US11253526B2 (en) 2022-02-22
US11633356B2 (en) 2023-04-25
CN106999427A (zh) 2017-08-01
RU2726193C2 (ru) 2020-07-09
AU2015329609B2 (en) 2021-01-21
AU2015329609A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
NI201500167A (es) Compuestos químicos
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP15014941A (es) Compuestos antivíricos para el vsr
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
CL2019000575A1 (es) Análogos de amilina.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
NI201500096A (es) Compuesto químicos
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
BR112017004798A2 (pt) composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
CL2017000223A1 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]